SEC Form 4 · accession 0001140361-18-023310
Spyre Therapeutics, Inc. · SYRE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Period of report
May 11, 2018
Accepted (ET)
May 14, 2018 · 4:01 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001636282
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | May 11, 2018 | S | 19,550 | $10.06 | D | 2,175,314 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Reflects sales of common stock executed in multiple transactions at prices ranging from $10.00 to $10.25. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- F2The shares are directly owned by Novartis Bioventures Ltd. Novartis Bioventures Ltd. is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities.